Your browser doesn't support javascript.
loading
The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma.
Robinson, S; Dreger, P; Caballero, D; Corradini, P; Geisler, C; Ghielmini, M; Le Gouill, S; Kimby, E; Rule, S; Vitolo, U; Dreyling, M; Hermine, O.
Afiliación
  • Robinson S; BMT Unit, University Hospital Bristol, Bristol, UK.
  • Dreger P; University of Heidelberg, Medizinische Klinik, Heidelberg, Germany.
  • Caballero D; Hospital Clínico Servicio de Hematologica, Salamanca, Spain.
  • Corradini P; Division of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, University of Milano, Milano, Italy.
  • Geisler C; BMT Unit, Rigshospitalet, Copenhagen, Denmark.
  • Ghielmini M; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.
  • Le Gouill S; CHU Nantes, Nantes, France.
  • Kimby E; Department Of Haematology, Karolinska University Hospital, Stockholm, Sweden.
  • Rule S; Plymouth Hospitals NHS Trust, Derriford Hospital, Plymouth, UK.
  • Vitolo U; Department of Oncology and Hematology, 'Città della Salute e della Scienza' University Hospital, Torino, Italy.
  • Dreyling M; Department of Haemato-Oncology, University of Munich, Munich, Germany.
  • Hermine O; Hôpital Necker, Service Hematologie Adulte, Paris, France.
Leukemia ; 29(2): 464-73, 2015 Feb.
Article en En | MEDLINE | ID: mdl-25034148
The role of both autologous (autoSCT) and allogeneic stem cell transplantation (alloSCT) in the management of mantle cell lymphoma (MCL) remains to be clarified. We conducted a consensus project using the RAND-modified Delphi consensus procedure to provide guidance on how SCT should be used in MCL. With regard to autoSCT, there was consensus in support of: autoSCT is the standard first-line consolidation therapy; induction therapy should include high-dose cytarabine and Rituximab; complete or partial remission should be achieved before autoSCT; Rituximab maintenance following autoSCT is not indicated; and omission of autoSCT in 'low-risk' patients is not indicated. No consensus could be reached regarding: autoSCT in the treatment of relapsed disease following non-transplant therapy; the value of positron emission tomography scanning and minimal residual disease (MRD) monitoring; in vivo purging with Rituximab; total body irradiation conditioning for autoSCT; and preemptive Rituximab after autoSCT. For alloSCT, consensus was reached in support of: alloSCT should be considered for patients relapsing after autoSCT; reduced intensity conditioning regimens should be used; allogeneic immunotherapy should be used for MRD eradication after alloSCT; and there is a lack of prognostic criteria to guide the use of alloSCT as first-line consolidation. No consensus was reached regarding the role of alloSCT for relapsed disease following non-transplant therapy.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trasplante Autólogo / Trasplante Homólogo / Trasplante de Células Madre Hematopoyéticas / Linfoma de Células del Manto Tipo de estudio: Guideline / Prognostic_studies Límite: Humans País/Región como asunto: Europa Idioma: En Revista: Leukemia Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2015 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trasplante Autólogo / Trasplante Homólogo / Trasplante de Células Madre Hematopoyéticas / Linfoma de Células del Manto Tipo de estudio: Guideline / Prognostic_studies Límite: Humans País/Región como asunto: Europa Idioma: En Revista: Leukemia Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2015 Tipo del documento: Article Pais de publicación: Reino Unido